ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Evaluation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV).

E. Aldag, T. Pedone, R. Pedersen, S. Besur, K. Safdar, A. Sahajpal.

Aurora St Luke's Medical Center, Milwaukee, WI.

Meeting: 2016 American Transplant Congress

Abstract number: C301

Keywords: Hepatitis C, Liver

Session Information

Date: Monday, June 13, 2016

Session Name: Poster Session C: Viruses and SOT

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Development of a Post-Graduate Year 2 Solid Organ Transplant Pharmacy Residency Program at an Academic Medical Center
  • Quality Improvement Initiative to Provide Comprehensive Pharmacy Services to Kidney Transplant Patients at a Small Transplant Center.

Background: Current guidelines recommend newer therapies over previous interferon-based treatments. The creation of a specialty pharmacy program within our institution that provides managed care for this patient population was implemented to promote adherence and accessibility of treatment.

Objective: To evaluate the impact of a specialty pharmacy program regarding the safety and efficacy with the use of current HCV regimens. The primary outcome is to evaluate efficacy based on sustained virologic response (SVR). The secondary outcome includes reviewing adverse drug reactions for safety.

Methods: A retrospective review of HCV patients who had prescriptions filled through a specialty pharmacy program between 1/17/14 and 6/30/15 was conducted. A total of 204 patients received prescriptions during the timeframe. Five (2.4%) were excluded due to de-enrolling from treatment. Kaplan-Meier Method was used to examine time to SVR after medication regimen completion.

Results: A total of 199 patients completed treatment with a mean age of 58 ± 9 years and 117 (59%) were male. Seventy-five (38%) had previously received treatment. A majority 156 (78%) of the patients were of HCV genotype 1 (119 (60% were 1A), 17 (8%) were genotype 2, and 20 (10%) were genotype 3. Roughly half, 105 (53%) of the patients were given LED/SOF ± Ribavirin, 37 (19%) received SOF/Ribavirin, 30 (15%) received SOF/SMV ± Ribavirin, 24 (12%) received SOF/PEG/Ribavirin, and 3 (1%) received another combination. At 6 months post-medication completion, 92% of patients had achieved SVR. There was no difference in SVR rates between those with previous treatment and those without (92% vs. 92% at 6 months, p=0.56). Those with HCV Genotype 1A had slightly lower SVR rates (87% vs. 98% at 6 months) though not statistically significant, p=0.11. The side effects reported are as followed: no side effects (56%), 32 (16%) headaches, 10 (5%) nausea, 5 (3%) anemia, and 17 (8%) other side effects.

Conclusion: SVR rates are comparable to clinical trials in this real-life clinical setting using a specialty pharmacy program. Those with HCV Genotype 1A had lower SVR rates post-medication completion, though it did not reach statistical significance. There was no difference in SVR rates between previously treated and treatment-naïve patients.

CITATION INFORMATION: Aldag E, Pedone T, Pedersen R, Besur S, Safdar K, Sahajpal A. Evaluation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV). Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Aldag E, Pedone T, Pedersen R, Besur S, Safdar K, Sahajpal A. Evaluation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV). [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/evaluation-of-the-impact-of-the-implementation-of-a-specialty-pharmacy-program-in-the-treatment-of-hepatitis-c-hcv/. Accessed March 5, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Role of Mitochondria, Metabolism and Inflammation: Pathways Influencing Short Term Outcomes Post-Renal Transplantation
    • Factors Influencing Creatinine Rise Following Donor Nephrectomy

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.